A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed Rituxan® in Patients With Rheumatoid Arthritis (RA) A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to ...